|
|
|
|
|
4233.1: Tuesday, November 9, 2004: 2:30 PM-4:00 PM | |||
Oral | |||
| |||
| The panel will consist of 'case studies' of mifepristone introduction in five countries: France, United States, Vietnam, Tunisia and India. Each panelist will present a brief history of mifepristone introduction in their country and review how, where and when women currently receive medical abortion (mifepristone coupled with the prostaglandin misoprostol). Panelists will highlight how drug registration and regulatory processes, pharmaceutical companies, traditions of abortion service provision, and public opinion have shaped availability and access to medical abortion. The discussion will explore the implications of these differences for both women and providers. Finally, panelists will suggest how these experiences may inform future efforts to expand access to safe abortion services or the introduction of other new reproductive health technologies. | |||
| Learning Objectives: At the end of this session, participants will be able to: 1) explain the process of mifepristone introduction in five countries (France, United States, Vietnam, Tunisia, and India) 2) identify implications of different drug regulatory schemes for the introduction and provision of medical abortion, and 3) compare different methods of medical abortion provision and identify important factors in successful delivery systems. | |||
| Beverly Winikoff, MD, MPH | |||
| Introduction and provision of medical abortion in France Danielle Hassoun, Dr, Andre Ullman, MD | |||
| Introduction and provision of medical abortion in the United States: Challenges and opportunities Beverly Winikoff, MD, MPH | |||
| Introduction and provision of medical abortion in Tunisia Selma Hajri, MD | |||
| Introduction of medical abortion in India Nozer Sheriar, MD | |||
| Introduction and provision of medical abortion in Vietnam Nguyen Thi Nhu Ngoc, MD | |||
| See individual abstracts for presenting author's disclosure statement and author's information. | |||
| Organized by: | Population, Family Planning, and Reproductive Health | ||
| Endorsed by: | APHA-Committee on Women's Rights; International Health; Public Health Nursing; Socialist Caucus; Women's Caucus | ||
| CE Credits: | CME, Health Education (CHES), Nursing | ||